Having lung cancer surgery can bring enormous relief—and then a new set of questions. If your oncologist has recommended osimertinib after surgery, you may wonder: If the tumour was removed, why do I need more treatment? Does this mean the cancer is still there? How much will it help?
Osimertinib is a targeted anti-cancer medicine. When it is used after complete surgery to reduce the risk of cancer returning, it is called adjuvant therapy. It is not a sign that surgery failed. Rather, it is an additional treatment intended to target cancer cells that may be too small to be seen on scans or tests.
This article is for general information and cannot replace advice from your thoracic surgeon or medical oncologist. Do not start, stop, or change osimertinib without their guidance.
Who may benefit from osimertinib after surgery?
Osimertinib is not suitable for every person who has had lung cancer surgery. It is used for adults with:
- Completely removed non-small cell lung cancer (NSCLC)
- An EGFR exon 19 deletion or EGFR exon 21 L858R mutation in the tumour
- Early-stage disease in the setting studied in ADAURA (stage IB–IIIA using the trial’s staging system)
This is why molecular testing of the tumour is so important. An EGFR mutation is a change in the cancer cells—not something caused by anything a patient did. Osimertinib works by blocking signals from certain EGFR-mutated cancer cells.
Why take treatment when the cancer has been removed?
Surgery removes the visible tumour and is often performed with curative intent. However, even after a successful operation, a small number of cancer cells can sometimes remain elsewhere in the body. They may be undetectable at the time of surgery but can later grow and cause a recurrence.
Adjuvant osimertinib is intended to lower that risk. It does not mean a recurrence has been found.
What did the ADAURA trial show?
The phase 3 ADAURA trial compared osimertinib with placebo in 682 people with completely resected, EGFR-mutated stage IB–IIIA NSCLC. Participants took osimertinib 80 mg once daily or placebo for up to three years. Some had received chemotherapy after surgery before entering the study; others had not. ADAURA updated disease-free survival analysis
The results were clinically important:
- In the overall trial population, the 4-year disease-free survival rate was 73% with osimertinib versus 38% with placebo.
- In stage II–IIIA disease, the 4-year disease-free survival rate was 70% versus 29%.
- Osimertinib also reduced the risk of recurrence in the brain/central nervous system.
- In the final overall-survival analysis, 5-year overall survival was 88% with osimertinib and 78% with placebo across the stage IB–IIIA population. Overall survival results from ADAURA
These figures describe groups of patients in a clinical trial; they cannot predict one individual’s outcome. Your recurrence risk depends on factors such as stage, lymph-node involvement, pathology findings, EGFR result, overall health, and other treatments received.
Is chemotherapy still needed?
Sometimes, yes. Osimertinib and chemotherapy play different roles.
For people whose cancer stage and health make postoperative platinum-based chemotherapy appropriate, the oncology team may recommend chemotherapy first, followed by osimertinib. In ADAURA, people could receive standard adjuvant chemotherapy before osimertinib, if their doctor and they chose it.
Do not assume that an EGFR-positive result automatically replaces chemotherapy. Ask your oncologist how your stage and surgical pathology affect the plan.
How is osimertinib usually taken?
In the adjuvant setting, the commonly used regimen is osimertinib 80 mg by mouth once daily, with or without food, for up to three years, or until recurrence or unacceptable side effects. If a dose is missed, patients should generally take the next dose at the usual time rather than doubling up. Follow your own prescription instructions. Prescribing information
Take it at roughly the same time each day. Let your oncology team know if swallowing tablets is difficult—there may be specific instructions for administration.
What side effects should patients expect?
Many people can continue daily routines while taking osimertinib, but side effects are possible and should be reported early. In ADAURA, common effects included:
- Diarrhoea
- Skin rash, acne-like changes, or dry skin
- Mouth soreness or ulcers
- Nail changes, tenderness, or inflammation around nails
- Fatigue
- Changes in blood counts
In the ADAURA safety data, diarrhoea and rash were common, while serious reactions were less common. Dose interruptions or dose reductions may help some people manage side effects; only the oncology team should make these changes. FDA prescribing information
When should I contact my cancer team urgently?
Call your oncology team promptly for new or worsening symptoms, especially:
- New or worsening breathlessness, cough, chest discomfort, or fever
- Severe or persistent diarrhoea, vomiting, dizziness, or inability to keep fluids down
- A painful, blistering, peeling, or widespread rash
- Palpitations, fainting, new swelling in the legs, or marked fatigue
- Eye pain, redness, blurred vision, or light sensitivity
- Unusual bruising, bleeding, fever, or signs of infection
Rare but serious risks include inflammation of the lungs (interstitial lung disease/pneumonitis), heart rhythm changes, heart-function problems, and significant skin or blood-related reactions. New breathing symptoms after lung surgery should never be dismissed as “just recovery.”
Will I need regular tests and scans?
Yes. Follow-up usually includes planned clinic visits and imaging to check for recurrence. Your doctor may also order blood tests and, depending on your health history and symptoms, heart monitoring such as an ECG or assessment of heart function.
Bring a complete list of prescription medicines, over-the-counter drugs, vitamins, and herbal products to every visit. Some medicines can interact with osimertinib. In particular, strong CYP3A inducers can lower osimertinib exposure, so do not add or stop medicines—including herbal remedies—without checking first. Drug-interaction information
What about pregnancy and breastfeeding?
Osimertinib can harm a developing baby. Discuss fertility, contraception, pregnancy plans, or breastfeeding with your oncology team before treatment begins. The medicine’s official prescribing information advises effective contraception during treatment and specific periods after the last dose; the exact guidance should be reviewed with your clinician. Safety information
Questions to ask at your next appointment
- What exactly did my pathology report show?
- Has my tumour been tested for EGFR, and which mutation was found?
- What is my individual risk of recurrence after surgery?
- Do you recommend chemotherapy before osimertinib? Why or why not?
- How long do you recommend I take osimertinib?
- Which side effects should prompt an urgent call?
- What tests and scans will I need during treatment?
- Could any of my current medicines or supplements interact with osimertinib?
- Who should I contact after hours if I develop breathlessness, fever, or severe diarrhoea?
The takeaway
For appropriately selected patients with fully removed, EGFR exon 19 deletion– or exon 21 L858R–positive NSCLC, adjuvant osimertinib has been shown in the ADAURA trial to substantially reduce the chance of recurrence and improve overall survival. It is a preventive treatment after surgery—not proof that cancer remains.
The right plan is personal. Review your pathology report, molecular-test result, stage, expected benefit, side effects, follow-up schedule, and affordability with your oncology team before beginning treatment.
